Drugs / ALPS12
last change Oct 2025 re-read 2 minutes ago

ALPS12

Developed for
small cell lung carcinoma
Investigated by
Chugai Pharmaceutical

Trials 1 · a red edge is where a trial was stopped

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07107490 Oct 2025 → Sep 2028 expected small cell lung carcinoma Chugai Pharmaceutical Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALPS12 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07107490
Route Intravenous “ALPS12 as an IV infusion” NCT07107490